{"id":"placebo-comparator-dosing","safety":{"commonSideEffects":[]},"_chembl":null,"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Placebo comparator dosing","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T06:52:53.338801+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T06:52:59.923962+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Placebo comparator dosing","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T06:53:00.906602+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3983509/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T06:53:01.434316+00:00"}},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo comparators are inert formulations used in randomized controlled trials to establish the efficacy and safety of a test drug by comparing outcomes in the treatment group versus the control group receiving placebo. The placebo effect and natural disease progression are accounted for through this comparison, allowing researchers to isolate the true pharmacological benefit of the investigational agent.","oneSentence":"A placebo comparator dosing regimen contains no active pharmaceutical ingredient and serves as a control arm in clinical trials to measure the effect of an investigational drug against baseline or standard care.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:00:42.805Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T06:53:03.369522+00:00","fieldsConflicting":0,"overallConfidence":0.95},"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT07433556","phase":"PHASE1","title":"Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of IY-828026 in Healthy Volunteers","status":"RECRUITING","sponsor":"Il-Yang Pharm. Co., Ltd.","startDate":"2026-03-23","conditions":"Healhty","enrollment":86},{"nctId":"NCT07494305","phase":"PHASE2","title":"Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE.","status":"RECRUITING","sponsor":"LB Pharmaceuticals Inc.","startDate":"2026-01-23","conditions":"Bipolar I Disorder","enrollment":320},{"nctId":"NCT06898606","phase":"PHASE1, PHASE2","title":"Psilocybe Cubensis Mushrooms With or Without Fluoxetine for Refractory Depression","status":"RECRUITING","sponsor":"Federal University of Latin American Integration","startDate":"2024-09-05","conditions":"Depressive Disorder","enrollment":24},{"nctId":"NCT03574909","phase":"PHASE3","title":"IRELAnD: Investigating the Role of Early Low-dose Aspirin in Diabetes","status":"COMPLETED","sponsor":"Royal College of Surgeons, Ireland","startDate":"2018-09-01","conditions":"Pre-Gestational Diabetes","enrollment":137},{"nctId":"NCT06564818","phase":"PHASE3","title":"\"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder\"","status":"RECRUITING","sponsor":"Cybin IRL Limited","startDate":"2024-12-17","conditions":"Major Depressive Disorder","enrollment":220},{"nctId":"NCT02965703","phase":"PHASE2","title":"Aspirin in Preventing Colorectal Cancer in Patients With Colorectal Adenoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-01-16","conditions":"Colorectal Adenoma, Colorectal Carcinoma","enrollment":81},{"nctId":"NCT04781387","phase":"PHASE2","title":"Evaluation of CRS3123 vs. Oral Vancomycin in Adult Patients With Clostridioides Difficile Infection","status":"COMPLETED","sponsor":"Crestone, Inc","startDate":"2021-01-05","conditions":"Clostridioides Difficile Infection","enrollment":43},{"nctId":"NCT05366855","phase":"PHASE3","title":"Study to Evaluate the Long-Term Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Subjects With GPP","status":"TERMINATED","sponsor":"Vanda Pharmaceuticals","startDate":"2022-04-21","conditions":"Generalized Pustular Psoriasis","enrollment":42},{"nctId":"NCT07290283","phase":"PHASE1","title":"A Study to Investigate Safety, Tolerability, and Pharmacokinetics of AZD3974 in Healthy Participants","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-12-10","conditions":"Healthy Participants","enrollment":176},{"nctId":"NCT07493031","phase":"PHASE1","title":"A PhaseⅠ Study of HW252001 in Healthy Subjects","status":"NOT_YET_RECRUITING","sponsor":"Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.","startDate":"2026-03-31","conditions":"IPF","enrollment":98},{"nctId":"NCT07037420","phase":"PHASE2","title":"ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly","status":"RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2025-10-28","conditions":"Acromegaly","enrollment":60},{"nctId":"NCT05965726","phase":"PHASE2","title":"RECOVER-VITAL: Platform Protocol, Appendix to Measure the Effects of Paxlovid on Long COVID Symptoms","status":"COMPLETED","sponsor":"Kanecia Obie Zimmerman","startDate":"2023-07-26","conditions":"Long COVID-19, Long COVID","enrollment":964},{"nctId":"NCT04734080","phase":"PHASE4","title":"Dronabinol in Total Knee Arthroplasty (TKA)","status":"COMPLETED","sponsor":"Hospital for Special Surgery, New York","startDate":"2021-03-09","conditions":"Total Knee Arthroplasty, Opioid Use","enrollment":114},{"nctId":"NCT07492771","phase":"PHASE1","title":"MP101 in Adults With Acute Pseudomonas Aeruginosa Pneumonia","status":"NOT_YET_RECRUITING","sponsor":"MicrobiotiX Co., Ltd","startDate":"2026-03","conditions":"Pneumonia - Bacterial, Pseudomonas Aeruginosa Infection","enrollment":18},{"nctId":"NCT06247345","phase":"PHASE1","title":"A Phase Ia/Ib, First-in-human (FIH) Study for Safety, Tolerability, Pharmacokinetics (PK), and Clinical Activity Evaluation of ADEL-Y01","status":"SUSPENDED","sponsor":"Alzheimer's Disease Expert Lab (ADEL), Inc.","startDate":"2024-02-06","conditions":"Alzheimer Disease","enrollment":73},{"nctId":"NCT04801849","phase":"PHASE2","title":"Vitamin E Dosing Study","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2022-08-05","conditions":"Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis","enrollment":200},{"nctId":"NCT07485764","phase":"PHASE4","title":"Metformin Combined With Secukinumab for Moderate-to-Severe Plaque Psoriasis in Overweight or Obese Chinese Patients","status":"NOT_YET_RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2026-06","conditions":"Psoriasis, Plaque Psoriasis, Moderate-to-severe Plaque Psoriasis","enrollment":186},{"nctId":"NCT07264192","phase":"PHASE1","title":"A Study of HS-10518 in Healthy Adult Premenopausal Females in China","status":"COMPLETED","sponsor":"West China Second University Hospital","startDate":"2025-03-11","conditions":"Infertility, Female","enrollment":60},{"nctId":"NCT07094542","phase":"PHASE2","title":"Jaw Muscle Pain Post Wisdom Molar Surgery","status":"NOT_YET_RECRUITING","sponsor":"Rutgers, The State University of New Jersey","startDate":"2026-05","conditions":"Post Operative Pain, Impacted Third Molar Tooth, Muscle Pain","enrollment":80},{"nctId":"NCT05568498","phase":"PHASE2","title":"Probiotic Treatment for Depression and Associated Mood Disorders in Parkinson's Disease","status":"RECRUITING","sponsor":"University of British Columbia","startDate":"2025-01-20","conditions":"Parkinson Disease, Depression, PARKINSON DISEASE (Disorder)","enrollment":60},{"nctId":"NCT05416229","phase":"PHASE2","title":"Psilocybin-assisted Therapy for Treatment of Alcohol Use Disorder","status":"COMPLETED","sponsor":"Anders Fink-Jensen, MD, DMSci","startDate":"2023-09-01","conditions":"Alcohol Use Disorder","enrollment":60},{"nctId":"NCT05120830","phase":"PHASE1, PHASE2","title":"NTLA-2002 in Adults With Hereditary Angioedema (HAE)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Intellia Therapeutics","startDate":"2021-12-10","conditions":"Hereditary Angioedema","enrollment":37},{"nctId":"NCT01946204","phase":"PHASE3","title":"A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Aragon Pharmaceuticals, Inc.","startDate":"2013-10-14","conditions":"Prostatic Neoplasms","enrollment":1207},{"nctId":"NCT06748053","phase":"PHASE2","title":"A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled Asthma","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-02-10","conditions":"Asthma","enrollment":307},{"nctId":"NCT07012395","phase":"PHASE2","title":"A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis","status":"RECRUITING","sponsor":"Spyre Therapeutics, Inc.","startDate":"2025-05-27","conditions":"Ulcerative Colitis, Inflammatory Bowel Diseases, Colitis","enrollment":645},{"nctId":"NCT05075824","phase":"PHASE2","title":"A Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab as Adjunct Treatment in Prevention of Vaso-Occlusive Episodes (VOE) in Sickle Cell Disease (SCD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-03-09","conditions":"Sickle Cell Disease","enrollment":90},{"nctId":"NCT06793397","phase":"PHASE3","title":"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder","status":"RECRUITING","sponsor":"Cybin IRL Limited","startDate":"2025-12-10","conditions":"Major Depressive Disorder (MDD), Depression in Adults, Depression - Major Depressive Disorder","enrollment":330},{"nctId":"NCT06698575","phase":"PHASE1","title":"A Study to Assess the Safety, Pharmacokinetics, and Tolerability of ABI-1179 in Healthy Subjects and in Subjects Seropositive for HSV-2 With Recurrent Genital Herpes","status":"COMPLETED","sponsor":"Assembly Biosciences","startDate":"2024-12-08","conditions":"Recurrent Genital Herpes Simplex Type 2","enrollment":103},{"nctId":"NCT07393360","phase":"NA","title":"Effect of a Food for Special Medical Purposes on Muscle Mass Preservation During GLP-1 RAs Weight Loss Treatment","status":"RECRUITING","sponsor":"Pharmanutra S.p.a.","startDate":"2025-12-11","conditions":"Obesity & Overweight","enrollment":144},{"nctId":"NCT07226895","phase":"PHASE1, PHASE2","title":"A Study Exploring Changes in a Variety of Biomarkers Following Dosing With MT1988 in Participants at Clinical High Risk for Psychosis","status":"RECRUITING","sponsor":"Monument Therapeutics Limited","startDate":"2026-03","conditions":"Clinical High Risk for Psychosis (CHR)","enrollment":150},{"nctId":"NCT07024823","phase":"PHASE1","title":"A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4248 in Healthy Participants and Participants With Chronic Kidney Disease and Type 2 Diabetes and to Assess Home Measurements of Creatinine in a Non Interventional Cohort","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-06-09","conditions":"Chronic Kidney Disease","enrollment":124},{"nctId":"NCT07224711","phase":"PHASE4","title":"The Impact of Perioperative Lidocaine Infusions on Enhanced Recovery After Non-Cardiac Surgery","status":"NOT_YET_RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2026-07-01","conditions":"Pain, Post Operative Analgesia, Opioid Consumption, Postoperative","enrollment":2290},{"nctId":"NCT06311682","phase":"PHASE3","title":"A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis","status":"RECRUITING","sponsor":"LEO Pharma","startDate":"2024-06-10","conditions":"Atopic Dermatitis","enrollment":195},{"nctId":"NCT05405387","phase":"PHASE2","title":"Impact of Budesonide on Incidence of ≥ Gr2 Diarrhea in Multiple Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplant","status":"RECRUITING","sponsor":"University of Utah","startDate":"2023-05-03","conditions":"Multiple Myeloma, Plasma Cell Leukemia","enrollment":120},{"nctId":"NCT06641466","phase":"PHASE3","title":"A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-03-11","conditions":"Menstrual Migraine","enrollment":723},{"nctId":"NCT06226883","phase":"PHASE2","title":"A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease","status":"RECRUITING","sponsor":"Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)","startDate":"2024-07-18","conditions":"Inflammatory Bowel Diseases, Crohn's Disease","enrollment":385},{"nctId":"NCT05430152","phase":"PHASE2","title":"Low-dose Naltrexone for Post-COVID Fatigue Syndrome","status":"COMPLETED","sponsor":"Luis Nacul","startDate":"2024-01-15","conditions":"Post-Viral Fatigue Syndrome","enrollment":160},{"nctId":"NCT07295509","phase":"PHASE2, PHASE3","title":"A Study of Picankibart in Patients With Active Psoriatic Arthritis","status":"RECRUITING","sponsor":"Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.","startDate":"2025-12-18","conditions":"Psoriatic Arthritis","enrollment":222},{"nctId":"NCT04543591","phase":"PHASE3","title":"Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2020-12-10","conditions":"Thrombotic Microangiopathy","enrollment":148},{"nctId":"NCT02489318","phase":"PHASE3","title":"A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Aragon Pharmaceuticals, Inc.","startDate":"2015-11-27","conditions":"Prostate Cancer","enrollment":1052},{"nctId":"NCT07048314","phase":"PHASE1, PHASE2","title":"Stem Cells for Erectile Dysfunction Post RALP","status":"NOT_YET_RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2026-03-10","conditions":"Erectile Dysfunction, Prostate Cancer","enrollment":40},{"nctId":"NCT06291376","phase":"PHASE3","title":"Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)","status":"RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2024-03-29","conditions":"Immunoglobulin A Nephropathy, IgAN","enrollment":510},{"nctId":"NCT03850964","phase":"PHASE2, PHASE3","title":"Effects of Pazopanib on Hereditary Hemorrhagic Telangiectasia Related Epistaxis and Anemia (Paz)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cure HHT","startDate":"2023-05-08","conditions":"Hereditary Hemorrhagic Telangiectasia, Epistaxis, Anemia","enrollment":70},{"nctId":"NCT06951711","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2025-06-13","conditions":"Bipolar Disorder Type I With Mania or Mania With Mixed Features","enrollment":274},{"nctId":"NCT07159841","phase":"PHASE2, PHASE3","title":"A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)","status":"RECRUITING","sponsor":"Crinetics Pharmaceuticals Inc.","startDate":"2026-01-22","conditions":"Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia","enrollment":153},{"nctId":"NCT07462819","phase":"PHASE1","title":"A Study to Evaluate the Safety and Tolerability of Intravenous Stemis™ in Elderly Subjects With Mild to Moderate Frailty Syndrome","status":"NOT_YET_RECRUITING","sponsor":"Ji Yan Biomedical Co., Ltd.","startDate":"2026-04","conditions":"Frailty Syndrome","enrollment":12},{"nctId":"NCT07392372","phase":"PHASE1","title":"A Clinical Trial Investigating the Safety and Biological Activity of the Antibody BNT351 in Adults Living Without and With HIV","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2026-02-09","conditions":"HIV -1 Infection","enrollment":61},{"nctId":"NCT01577082","phase":"PHASE3","title":"Efficacy and Safety of CHF 1535 200/6µg in Not Adequately Controlled Asthmatic Patients","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2012-04-20","conditions":"Asthma","enrollment":542},{"nctId":"NCT03844412","phase":"PHASE2","title":"Vestibulodynia: Understanding Pathophysiology and Determining Appropriate Treatments","status":"COMPLETED","sponsor":"Duke University","startDate":"2019-11-04","conditions":"Vestibulodynia, Temporomandibular Disorder, Fibromyalgia Syndrome","enrollment":209},{"nctId":"NCT07161999","phase":"PHASE2","title":"Study of COYA 302 for the Treatment of ALS","status":"RECRUITING","sponsor":"Coya Therapeutics","startDate":"2025-10-01","conditions":"Amyotrophic Lateral Sclerosis (ALS)","enrollment":120},{"nctId":"NCT06378697","phase":"PHASE3","title":"A Phase III Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Active Ankylosing Spondylitis","status":"COMPLETED","sponsor":"Akeso","startDate":"2023-11-22","conditions":"Ankylosing Spondylitis","enrollment":510},{"nctId":"NCT06342713","phase":"PHASE1","title":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and in Adults With Autoimmune Dermatological Diseases","status":"RECRUITING","sponsor":"BeiGene","startDate":"2024-06-20","conditions":"Healthy Participants, Healthy Subjects, Healthy Volunteers","enrollment":211},{"nctId":"NCT06040086","phase":"PHASE3","title":"Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2023-09-22","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":1454},{"nctId":"NCT05538208","phase":"PHASE2","title":"The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study","status":"RECRUITING","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2024-06-07","conditions":"Lupus Nephritis","enrollment":105},{"nctId":"NCT07480018","phase":"NA","title":"Berberine Supplementation, Sprint Interval Training, and Immune Function Study","status":"RECRUITING","sponsor":"University of Northern Colorado","startDate":"2026-01-01","conditions":"Berberine, Sprint Training, Wellbeing","enrollment":40},{"nctId":"NCT07479550","phase":"PHASE2","title":"Anesthesia-Masked Psilocybin Therapy for Major Depression","status":"NOT_YET_RECRUITING","sponsor":"Stanford University","startDate":"2026-07","conditions":"Major Depression","enrollment":10},{"nctId":"NCT06951698","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2025-06-11","conditions":"Bipolar-I Disorder With Mania or Mania With Mixed Features","enrollment":274},{"nctId":"NCT06102005","phase":"PHASE2","title":"Dose Ranging Study of Lunsekimig Compared With Placebo-control in Adult Participants With Moderate-to-severe Asthma","status":"COMPLETED","sponsor":"Sanofi","startDate":"2023-10-16","conditions":"Asthma","enrollment":685},{"nctId":"NCT07351058","phase":"PHASE3","title":"A Clinical Study to Evaluate the Effects of RO7795068 in Participants With Obesity or Overweight and Type 2 Diabetes","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2026-03-31","conditions":"Obesity or Overweight, Type 2 Diabetes Mellitus","enrollment":1600},{"nctId":"NCT07271693","phase":"PHASE1","title":"A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7806881 in Healthy Participants","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2025-12-22","conditions":"Healthy Volunteers","enrollment":128},{"nctId":"NCT07219420","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis","status":"RECRUITING","sponsor":"UCB Biopharma SRL","startDate":"2025-11-14","conditions":"Palmoplantar Pustulosis","enrollment":320},{"nctId":"NCT07474753","phase":"NA","title":"Coffee Increases Physical and Cognitive Performance Both in Men and Women","status":"COMPLETED","sponsor":"Northumbria University","startDate":"2020-12-04","conditions":"Dietary Supplement, Exercise","enrollment":69},{"nctId":"NCT07473570","phase":"PHASE1","title":"A Study（Phase I）of GS3-007a Dry Suspension in Healthy Chinese Adults","status":"RECRUITING","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","startDate":"2026-01-07","conditions":"Healthy Adults","enrollment":32},{"nctId":"NCT06582888","phase":"EARLY_PHASE1","title":"Advancing VR-based Attentional Bias as a Biomarker for Tobacco Use Disorder","status":"RECRUITING","sponsor":"University of California, San Diego","startDate":"2024-11-19","conditions":"Nicotine Addiction, Craving","enrollment":200},{"nctId":"NCT07298434","phase":"PHASE3","title":"Study of VYD2311 for the Prevention of COVID-19","status":"ACTIVE_NOT_RECRUITING","sponsor":"Invivyd, Inc.","startDate":"2026-01-08","conditions":"COVID-19","enrollment":1770},{"nctId":"NCT05935761","phase":"PHASE2","title":"Investigating Novel Interventions for Low Back Pain in US Military Veterans: A Randomized Controlled Adaptive Phase II Trial","status":"NOT_YET_RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2026-06-01","conditions":"Chronic Low Back Pain","enrollment":108},{"nctId":"NCT07351045","phase":"PHASE3","title":"A Clinical Study to Evaluate the Effects of RO7795068 in Participants With Obesity or Overweight Without Type 2 Diabetes","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2026-03-31","conditions":"Obesity or Overweight","enrollment":2000},{"nctId":"NCT06602453","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of GDC-8264 in Preventing Cardiac Surgery-Associated Acute Kidney Injury (AKI) and Major Adverse Kidney Events (MAKE)","status":"TERMINATED","sponsor":"Genentech, Inc.","startDate":"2025-01-17","conditions":"Acute Kidney Injury","enrollment":67},{"nctId":"NCT07126262","phase":"PHASE2","title":"A Study of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 to < 36 Months","status":"RECRUITING","sponsor":"BioMarin Pharmaceutical","startDate":"2025-07-30","conditions":"Hypochondroplasia","enrollment":60},{"nctId":"NCT04175600","phase":"PHASE3","title":"A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension","status":"ACTIVE_NOT_RECRUITING","sponsor":"Actelion","startDate":"2020-01-16","conditions":"Hypertension, Pulmonary","enrollment":138},{"nctId":"NCT06579690","phase":"PHASE3","title":"Use of Preoperative Sodium Bicarbonate Among Women With Obstructed Labor","status":"RECRUITING","sponsor":"Busitema University","startDate":"2025-05-06","conditions":"Obstructed Labor","enrollment":472},{"nctId":"NCT05742802","phase":"PHASE3","title":"Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO).","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2023-03-06","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":1713},{"nctId":"NCT06705764","phase":"PHASE4","title":"Tezepelumab in the Treatment of Emergency Room Asthma in Adults (TERAA)","status":"NOT_YET_RECRUITING","sponsor":"University of Alberta","startDate":"2026-04-01","conditions":"Severe Asthma","enrollment":100},{"nctId":"NCT06542497","phase":"PHASE3","title":"Evaluate Efficacy and Safety of POS to Improve Distance-corrected Near Visual in Participants With Presbyopia","status":"COMPLETED","sponsor":"Ocuphire Pharma, Inc.","startDate":"2024-08-15","conditions":"Presbyopia","enrollment":569},{"nctId":"NCT06214403","phase":"PHASE2","title":"Antimicrobial Resistant Organism Decolonization After Microbiome Perturbation","status":"WITHDRAWN","sponsor":"University Health Network, Toronto","startDate":"2026-07","conditions":"Gram-negative Bacteremia, Microbial Colonization, Antibiotic Resistant Infection","enrollment":""},{"nctId":"NCT03451851","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2018-07-11","conditions":"Psoriasis","enrollment":120},{"nctId":"NCT06079281","phase":"PHASE3","title":"Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase Alfa","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2024-01-03","conditions":"Hypophosphatasia","enrollment":124},{"nctId":"NCT07112872","phase":"PHASE2","title":"A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 Diabetes","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2025-08-19","conditions":"Type 2 Diabetes Mellitus","enrollment":240},{"nctId":"NCT06349759","phase":"PHASE3","title":"Safety and Efficacy of 0.75% Phentolamine Ophthalmic Solution in Subjects With Post-refractive Surgery Visual Disturbances","status":"COMPLETED","sponsor":"Ocuphire Pharma, Inc.","startDate":"2024-04-01","conditions":"Mesopic Vision, Night Vision Loss","enrollment":200},{"nctId":"NCT07466251","phase":"PHASE4","title":"PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke","status":"NOT_YET_RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2026-09-01","conditions":"Acute Ischemic Stroke AIS, Intracranial Atherosclerosis ICAS, Atherosclerotic Plaque","enrollment":1212},{"nctId":"NCT06717698","phase":"PHASE2","title":"A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease","status":"RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2024-12-02","conditions":"Chronic Kidney Disease","enrollment":465},{"nctId":"NCT04192136","phase":"NA","title":"NAD+ and Exercise in FA","status":"COMPLETED","sponsor":"Children's Hospital of Philadelphia","startDate":"2020-09-03","conditions":"Friedreich Ataxia 1","enrollment":75},{"nctId":"NCT05658575","phase":"PHASE2, PHASE3","title":"Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare","status":"RECRUITING","sponsor":"Olatec Therapeutics LLC","startDate":"2023-01-06","conditions":"Acute Gout Flare, Gout Attack, Gout Flare","enrollment":300},{"nctId":"NCT07262281","phase":"PHASE1","title":"Evaluation of the Safety, Tolerability and Pharmacokinetics of HY6725 in Healthy Adult Participants","status":"RECRUITING","sponsor":"Newsoara Biopharma Co., Ltd.","startDate":"2026-02-06","conditions":"Healthy","enrollment":74},{"nctId":"NCT06899815","phase":"PHASE1","title":"Preliminary Human Trials of F230 Tablets","status":"RECRUITING","sponsor":"Beijing Continent Pharmaceutical Co, Ltd.","startDate":"2025-05-15","conditions":"Pulmonary Hypertension","enrollment":136},{"nctId":"NCT06641089","phase":"PHASE3","title":"Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response","status":"RECRUITING","sponsor":"MoonLake Immunotherapeutics AG","startDate":"2024-10-15","conditions":"Arthritis, Psoriatic","enrollment":600},{"nctId":"NCT07281703","phase":"PHASE1","title":"Evaluation of the Safety, Tolerability and Pharmacokinetics of HY8931 in Healthy Adult Participants","status":"RECRUITING","sponsor":"Newsoara Biopharma Co., Ltd.","startDate":"2026-01-14","conditions":"Healthy","enrollment":60},{"nctId":"NCT06897748","phase":"PHASE2","title":"A Study to Investigate Efficacy and Safety of Tozorakimab Injections Compared With Placebo in Adult Participants With Symptomatic Chronic Obstructive Pulmonary Disease (COPD) With a History of COPD Exacerbations and Elevated Eosinophils","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2025-04-12","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":98},{"nctId":"NCT02712723","phase":"PHASE2","title":"Letrozole Plus Ribociclib or Placebo as Neo-adjuvant Therapy in ER-positive, HER2-negative Early Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Qamar Khan","startDate":"2016-02","conditions":"Breast Cancer","enrollment":121},{"nctId":"NCT07459959","phase":"PHASE1, PHASE2","title":"LiO-AD: Lithium Orotate in Alzheimers Disease Feasibility, Biomarker Engagement, and Clinical Response","status":"NOT_YET_RECRUITING","sponsor":"Johns Hopkins University","startDate":"2026-06-01","conditions":"Alzheimer s Disease","enrollment":40},{"nctId":"NCT06783309","phase":"PHASE1, PHASE2","title":"CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D)","status":"RECRUITING","sponsor":"COUR Pharmaceutical Development Company, Inc.","startDate":"2025-05-12","conditions":"Type 1 Diabetes Mellitus, T1D, T1DM","enrollment":72},{"nctId":"NCT06671938","phase":"PHASE2","title":"Safety, Tolerability, and Pharmacokinetics of Exidavnemab in Patients With Parkinson's Disease and Patients With Multiple System Atrophy","status":"ACTIVE_NOT_RECRUITING","sponsor":"BioArctic AB","startDate":"2024-10-24","conditions":"Parkinson Disease, Multiple System Atrophy","enrollment":38},{"nctId":"NCT06931977","phase":"NA","title":"Natural Product System and Lifestyle Modification","status":"COMPLETED","sponsor":"dōTERRA International","startDate":"2025-04-29","conditions":"Healthy","enrollment":97},{"nctId":"NCT05138757","phase":"PHASE1, PHASE2","title":"Pinpoint Trial: Prebiotics IN Peanut Oral ImmunoTherapy","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2021-11-30","conditions":"Peanut Allergy","enrollment":20},{"nctId":"NCT07123467","phase":"PHASE3","title":"Cannabidiol-Assisted Learning for Managing Generalized Anxiety Disorder","status":"RECRUITING","sponsor":"Wayne State University","startDate":"2025-11-03","conditions":"Generalized Anxiety Disorder (GAD), Anxiety Disorders","enrollment":90},{"nctId":"NCT06979336","phase":"PHASE2","title":"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)","status":"RECRUITING","sponsor":"Genentech, Inc.","startDate":"2025-09-29","conditions":"Ulcerative Colitis","enrollment":224},{"nctId":"NCT06028126","phase":"NA","title":"Superficial Parasternal Intercostal Plane Block in Cardiac Surgery Trial","status":"COMPLETED","sponsor":"Unity Health Toronto","startDate":"2023-09-08","conditions":"Post-operative Pain, Post-operative Delirium, Post-cardiac Surgery","enrollment":340},{"nctId":"NCT07456449","phase":"NA","title":"Collagen Peptides and Cellular Aging","status":"NOT_YET_RECRUITING","sponsor":"University of Vienna","startDate":"2026-02","conditions":"Longevity, Healthy Aging, Biological Ageing","enrollment":125},{"nctId":"NCT04206553","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2020-10-28","conditions":"Bullous Pemphigoid","enrollment":106},{"nctId":"NCT07258394","phase":"PHASE3","title":"Clinical Study for Dimethyl Fumarate in Preserving Islet β-Cell Function in Type 1 Diabetes Mellitus","status":"RECRUITING","sponsor":"Nanjing Medical University","startDate":"2026-01-27","conditions":"Type 1 Diabetes","enrollment":90}],"_emaApprovals":[],"_faersSignals":[],"crossReferences":{"chemblId":"CHEMBL3983509"},"_approvalHistory":[],"publicationCount":4715,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Placebo comparator dosing","genericName":"Placebo comparator dosing","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AZD4076 is a small molecule being studied in clinical trials for various conditions, including Non-alcoholic Steatohepatitis (NASH), Diabetic Neuropathies, and Diabetes Mellitus, Type 2. In the clinical trial NCT02612662, AZD4076 was compared to a placebo in a single-blind, placebo-controlled study to assess its safety, tolerability, and pharmacokinetics in healthy male subjects.","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T06:53:03.369522+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}